Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma : A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
© 2020 American Cancer Society..
BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first-line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) sites.
METHODS: The inclusion criteria were a confirmed histological diagnosis, treatment between January 2010 and December 2015, measurable disease (Response Evaluation Criteria in Solid Tumors 1.1), an Eastern Cooperative Oncology Group performance status ≤2, and an age ≥ 18 years. The endpoints were progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). PFS was analyzed with methods for interval-censored data. Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for histology, grade, age, sex, performance status, tumor site, and tumor extent.
RESULTS: Three hundred three patients from 18 EORTC-STBSG sites were identified. One hundred seventeen (39%) received doxorubicin plus dacarbazine, 71 (23%) received doxorubicin plus ifosfamide, and 115 (38%) received doxorubicin. In the 2:1:2 propensity score-matched population (205 patients), the estimated median PFS was 9.2 months (95% confidence interval [CI], 5.2-9.7 months), 8.2 months (95% CI, 5.2-10.1 months), and 4.8 months (95% CI, 2.3-6.0 months) with ORRs of 30.9%, 19.5%, and 25.6% for doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer with doxorubicin plus dacarbazine versus doxorubicin (hazard ratio [HR], 0.72; 95% CI, 0.52-0.99). Doxorubicin plus dacarbazine was associated with longer OS (median, 36.8 months; 95% CI, 27.9-47.2 months) in comparison with both doxorubicin plus ifosfamide (median, 21.9 months; 95% CI, 16.7-33.4 months; HR, 0.65; 95% CI, 0.40-1.06) and doxorubicin (median, 30.3 months; 95% CI, 21.0-36.3 months; HR, 0.66; 95% CI, 0.43-0.99). Adjusted analyses retained an effect for PFS but not for OS. None of the factors selected for multivariate analysis had a significant interaction with the received treatment for both PFS and OS.
CONCLUSIONS: This is the largest retrospective study of first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials.
| Errataetall: |
CommentIn: Cancer. 2020 Oct 15;126(20):4615-4616. - PMID 32767667 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:126 |
|---|---|
| Enthalten in: |
Cancer - 126(2020), 11 vom: 01. Juni, Seite 2637-2647 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
7GR28W0FJI |
|---|
| Anmerkungen: |
Date Completed 22.01.2021 Date Revised 12.05.2021 published: Print-Electronic CommentIn: Cancer. 2020 Oct 15;126(20):4615-4616. - PMID 32767667 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.32795 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307211886 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307211886 | ||
| 003 | DE-627 | ||
| 005 | 20231225125052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.32795 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1024.xml |
| 035 | |a (DE-627)NLM307211886 | ||
| 035 | |a (NLM)32129883 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a D'Ambrosio, Lorenzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma |b A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 12.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cancer. 2020 Oct 15;126(20):4615-4616. - PMID 32767667 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 American Cancer Society. | ||
| 520 | |a BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first-line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) sites | ||
| 520 | |a METHODS: The inclusion criteria were a confirmed histological diagnosis, treatment between January 2010 and December 2015, measurable disease (Response Evaluation Criteria in Solid Tumors 1.1), an Eastern Cooperative Oncology Group performance status ≤2, and an age ≥ 18 years. The endpoints were progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). PFS was analyzed with methods for interval-censored data. Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for histology, grade, age, sex, performance status, tumor site, and tumor extent | ||
| 520 | |a RESULTS: Three hundred three patients from 18 EORTC-STBSG sites were identified. One hundred seventeen (39%) received doxorubicin plus dacarbazine, 71 (23%) received doxorubicin plus ifosfamide, and 115 (38%) received doxorubicin. In the 2:1:2 propensity score-matched population (205 patients), the estimated median PFS was 9.2 months (95% confidence interval [CI], 5.2-9.7 months), 8.2 months (95% CI, 5.2-10.1 months), and 4.8 months (95% CI, 2.3-6.0 months) with ORRs of 30.9%, 19.5%, and 25.6% for doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer with doxorubicin plus dacarbazine versus doxorubicin (hazard ratio [HR], 0.72; 95% CI, 0.52-0.99). Doxorubicin plus dacarbazine was associated with longer OS (median, 36.8 months; 95% CI, 27.9-47.2 months) in comparison with both doxorubicin plus ifosfamide (median, 21.9 months; 95% CI, 16.7-33.4 months; HR, 0.65; 95% CI, 0.40-1.06) and doxorubicin (median, 30.3 months; 95% CI, 21.0-36.3 months; HR, 0.66; 95% CI, 0.43-0.99). Adjusted analyses retained an effect for PFS but not for OS. None of the factors selected for multivariate analysis had a significant interaction with the received treatment for both PFS and OS | ||
| 520 | |a CONCLUSIONS: This is the largest retrospective study of first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a dacarbazine | |
| 650 | 4 | |a doxorubicin | |
| 650 | 4 | |a ifosfamide | |
| 650 | 4 | |a leiomyosarcoma | |
| 650 | 4 | |a propensity score | |
| 650 | 4 | |a retrospective study | |
| 650 | 4 | |a sarcoma | |
| 650 | 7 | |a Dacarbazine |2 NLM | |
| 650 | 7 | |a 7GR28W0FJI |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Ifosfamide |2 NLM | |
| 650 | 7 | |a UM20QQM95Y |2 NLM | |
| 700 | 1 | |a Touati, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Blay, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Grignani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Flippot, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Czarnecka, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Piperno-Neumann, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Broto, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Sanfilippo, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Duffaud, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Vincenzi, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Daniel P |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzeo, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Tuchscherer, Armin |e verfasserin |4 aut | |
| 700 | 1 | |a Chevreau, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Sherriff, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Estival, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Litière, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Sents, Ward |e verfasserin |4 aut | |
| 700 | 1 | |a Ray-Coquard, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Tolomeo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Le Cesne, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Rutkowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Stacchiotti, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Kasper, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Gelderblom, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Gronchi, Alessandro |e verfasserin |4 aut | |
| 700 | 0 | |a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 126(2020), 11 vom: 01. Juni, Seite 2637-2647 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:126 |g year:2020 |g number:11 |g day:01 |g month:06 |g pages:2637-2647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.32795 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 126 |j 2020 |e 11 |b 01 |c 06 |h 2637-2647 | ||